Less traumatic surgery


Rapid technology advancements have given narrow gauge surgery the edge in diabetic cases

Vitrectomy has been proven as an effective treatment for patients with proliferative diabetic retinopathy (PDR) and many surgeons are now using narrow gauge instrumentation to perform the surgery. However, previous literature has revealed some potential disadvantages to the technique and it has been questioned whether narrow gauge surgery is associated with an increased rate of peripheral retinal break formation in macular surgery and also of relevance, a lower success rate in retinal reattachment surgery than 20G surgery.1,2

Achieving the surgical aims

To examine the incidence of retinal break formation in patients being treated for PDR, Dr Steel and colleagues retrospectively reviewed a group of 170 eyes. Half of the eyes comprised the control group and underwent conventional 20G surgery and the other half were treated with 23G transconjunctival vitrectomy surgery.

"We analysed a variety of factors in the case mix to see if the groups could be compared in a meaningful way including basic demographics, for example, it is known younger patients have a higher incidence of retinal break formation during diabetic vitrectomy, as well as a variety of metabolic indicators (e.g., HbAic)," added Dr Steel. "We also looked at the surgery performed - hence analysed the proportion of combined cases and in particular and importantly the extent and position of vitreoretinal adhesion, which defines the complexity of the cases."

Dr Steel reported that while he was transitioning from using 20G to 23G surgery he continued to perform the former technique on complex cases. Therefore, he excluded patients that were operated on during that period from the study.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.